zagociguat
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2021 (NCT04798989)
Timeline
Indications
Mechanism of action
NPR1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Fc1ccccc1Cc1nc(-c2nc(C(F)(F)F)n[nH]2)cn2ccnc12- Mol. weight
- 362.29 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314620 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06961344 | Phase 2 | Aug 18, 2025 | Tisento Therapeutics |
| NCT06402123 | Phase 2 | Sep 10, 2024 | Tisento Therapeutics |
| NCT04972227 | Phase 1 | Sep 10, 2021 | Cyclerion Therapeutics, Inc. |
| NCT04798989 | Phase 2 | Jun 1, 2021 | Cyclerion Therapeutics, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cyclerion Therapeutics, Inc. | For profit | 2 | 2 | 2 | 2021 |
| Tisento Therapeutics | For profit | 2 | 2 | 1 | 2024 |
2 organizations
Page 1 / 1